Previously submitted to: JMIR Research Protocols (no longer under consideration since Nov 12, 2020)
Date Submitted: Oct 17, 2020
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
The Pregnancy Outcomes and Child Development Effects of SARS-CoV-2 Infection Study (PROUDEST): A Multicenter Prospective Cohort Study Protocol
ABSTRACT
Background:
A growing body of evidence suggests that infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) during pregnancy may affect maternal-fetal outcomes, with possible implications for the long-term development of exposed children
Objective:
The PRegnancy OUtcomes and child Development Effects of SARS-CoV-2 infection STudy (PROUDEST) is a multicenter prospective study designed to understand the repercussions of COVID-19 to mother-child global health.
Methods:
The PROUDEST trial comprises two prospective sequential substudies. The PREGNANT substudy will assess the effects of SARS-CoV-2 infection on pregnancy, childbirth and puerperium clinically and from a mechanistic standpoint to understand the inflammatory and immunological phenomena underlying COVID-19 in relation to pregnancy. Pregnant women aged 18 to 40 years with laboratory-proven exposure to SARS-CoV-2 (group A, n = 300) will be compared to control subjects with no laboratory evidence of in-pregnancy exposure to the virus (group B, n = 300). Subjects exposed to other infections during pregnancy will be excluded. The BORN substudy is a long-term follow-up study assessing the offspring of women who entered the prior substudy. It will describe the effects of SARS-CoV-2 exposure during pregnancy on children’s growth, neurodevelopment and metabolism from birth up to five years of age. It includes two comparison groups: group A (exposed, n = 300) comprises children born from SARS-CoV-2-exposed pregnancies, and group B (controls, n = 300) comprises children from nonexposed mothers.
Results:
The recruitment has begun in July, 2020 and until September, 2020, 115 pregnant women infected with SARS-CoV-2 during pregnancy and 80 newborns were included. Data analysis is scheduled to start after all inclusion data have been collected.
Conclusions:
Upon completion of the study, we expect to have obtained comprehensive data to provide a better understanding of the effects of SARS-CoV-2 and its inflammatory and immunological processes on pregnancy, puerperium and infancy. Our findings will inform clinical decisions regarding the care of exposed mothers and children and support the development of evidence-based public health policies. Clinical Trial: The PROUDEST study was registered on the Brazilian Register of Clinical Trials website (https://www. http://www.ensaiosclinicos.gov.br), ID RBR-65qxs2, on June 13th, 2020, where Brazilian clinical trials are exclusively registered.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.